Barclays raised the firm’s price target on Boston Scientific to $86 from $78 and keeps an Overweight rating on the shares. The firm made a number of revisions to the company’s model, raising both sales and earnings estimates to be in-line with management’s outlook and commentary.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Jefferies healthcare analyst to hold an analyst/industry conference call
- Boston Scientific Appoints New Director and Expands Board
- Boston Scientific removed from ‘Analyst Current Favorites’ at Raymond James
- Boston Scientific price target raised to $91 from $85 at Raymond James
- Boston Scientific price target raised to $78 from $73 at Deutsche Bank